Vor Biopharma Inc. SEC filings VOR
Vor Biopharma Inc. has 462 filings in SEC EDGAR's recent list, going back to Jul 10, 2020. Its latest annual report, Form ARS, was filed on Apr 27, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Oct 30, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Jul 7, 2026 (officer or director change). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 424B5 | Prospectus supplement | Oct 30, 2026 | — |
| 10-Q | Quarterly report | Oct 30, 2026 | Sep 30, 2026 |
| S-3ASR | Automatic shelf registration | Sep 4, 2026 | — |
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Officer or director change
|
Jul 7, 2026 | Jul 6, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 12, 2026 | Jun 11, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 8, 2026 | Jun 8, 2026 |
| 10-Q | Quarterly report | May 13, 2026 | Mar 31, 2026 |
| EFFECT | Filing | May 6, 2026 | — |
| CORRESP | Letter to the SEC | May 4, 2026 | — |
| UPLOAD | Letter from the SEC | May 1, 2026 | — |
| S-3 | Shelf registration | Apr 27, 2026 | — |
| ARS | Annual report to shareholders | Apr 27, 2026 | Dec 31, 2025 |
| DEFA14A | Additional proxy material | Apr 27, 2026 | — |
| DEF 14A | Proxy statement | Apr 27, 2026 | Apr 23, 2026 |
| S-8 | Employee stock plan registration | Mar 30, 2026 | — |
| 10-K | Annual report | Mar 30, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Mar 27, 2026 | Mar 26, 2026 |
| 424B3 | Prospectus | Feb 5, 2026 | — |
| EFFECT | Filing | Feb 4, 2026 | — |
| CORRESP | Letter to the SEC | Feb 2, 2026 | — |
| UPLOAD | Letter from the SEC | Jan 30, 2026 | — |
| S-3 | Shelf registration | Jan 29, 2026 | — |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Jan 12, 2026 | Jan 12, 2026 |
| 8-K |
Current report
Officer or director change
|
Jan 2, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Officer or director change, Regulation FD disclosure
|
Dec 18, 2025 | Dec 15, 2025 |
| 8-K |
Current report
Officer or director change
|
Dec 9, 2025 | Dec 5, 2025 |
| 424B3 | Prospectus | Dec 1, 2025 | — |
| 10-Q | Quarterly report | Nov 13, 2025 | Sep 30, 2025 |
| 8-K |
Current report
Other events
|
Nov 12, 2025 | Nov 10, 2025 |
| 424B5 | Prospectus supplement | Nov 12, 2025 | — |
| 424B5 | Prospectus supplement | Nov 10, 2025 | — |
| S-3/A | Filing | Nov 10, 2025 | — |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Nov 3, 2025 | Nov 2, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 28, 2025 | Oct 28, 2025 |
| UPLOAD | Letter from the SEC | Sep 30, 2025 | — |
| S-8 | Employee stock plan registration | Sep 24, 2025 | — |
| S-3 | Shelf registration | Sep 24, 2025 | — |
| 8-K |
Current report
Change to shareholder rights, Other events
|
Sep 17, 2025 | Sep 17, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 2, 2025 | Sep 2, 2025 |
| 8-K |
Current report
Officer or director change
|
Aug 27, 2025 | Aug 25, 2025 |
| 8-K |
Current report
Officer or director change, Shareholder vote results, Other events
|
Aug 27, 2025 | Aug 25, 2025 |
| 424B5 | Prospectus supplement | Aug 27, 2025 | — |
| 10-Q | Quarterly report | Aug 12, 2025 | Jun 30, 2025 |
| DEF 14A | Proxy statement | Aug 8, 2025 | Aug 25, 2025 |
| PRE 14A | Preliminary proxy statement | Jul 29, 2025 | Jul 29, 2025 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jul 22, 2025 | Jul 16, 2025 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jul 10, 2025 | Jul 9, 2025 |
| 8-K |
Current report
Material agreement, Agreement ended, Unregistered share sale, Officer or director change, Regulation FD disclosure
|
Jun 26, 2025 | Jun 25, 2025 |
| 8-K |
Current report
Bylaw or fiscal year change, Shareholder vote results
|
May 23, 2025 | May 22, 2025 |
| 8-K |
Current report
Officer or director change
|
May 20, 2025 | May 19, 2025 |
| 10-Q | Quarterly report | May 14, 2025 | Mar 31, 2025 |
| 8-K |
Current report
Exit or restructuring costs, Officer or director change, Other events
|
May 8, 2025 | May 5, 2025 |
| DEFR14A | Filing | Apr 30, 2025 | — |
| 8-K |
Current report
Listing notice
|
Apr 25, 2025 | Apr 22, 2025 |
| ARS | Annual report to shareholders | Apr 8, 2025 | Dec 31, 2024 |
| DEFA14A | Additional proxy material | Apr 8, 2025 | — |
| DEF 14A | Proxy statement | Apr 8, 2025 | May 22, 2025 |
| 8-K |
Current report
Officer or director change
|
Apr 3, 2025 | Mar 31, 2025 |
| EFFECT | Filing | Mar 31, 2025 | — |
| PRE 14A | Preliminary proxy statement | Mar 28, 2025 | May 22, 2025 |
| CORRESP | Letter to the SEC | Mar 27, 2025 | — |
| UPLOAD | Letter from the SEC | Mar 26, 2025 | — |
| S-8 | Employee stock plan registration | Mar 20, 2025 | — |
| S-3 | Shelf registration | Mar 20, 2025 | — |
| 10-K | Annual report | Mar 20, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Officer or director change
|
Feb 6, 2025 | Feb 3, 2025 |
| EFFECT | Filing | Jan 29, 2025 | — |
| 424B3 | Prospectus | Jan 29, 2025 | — |
| CORRESP | Letter to the SEC | Jan 27, 2025 | — |
| UPLOAD | Letter from the SEC | Jan 27, 2025 | — |
| S-3 | Shelf registration | Jan 21, 2025 | — |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jan 8, 2025 | Jan 6, 2025 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure, Other events
|
Dec 27, 2024 | Dec 26, 2024 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Dec 9, 2024 | Dec 9, 2024 |
| 10-Q | Quarterly report | Nov 7, 2024 | Sep 30, 2024 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Sep 30, 2024 | Sep 30, 2024 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 5, 2024 | Sep 5, 2024 |
| 8-K |
Current report
Listing notice
|
Aug 30, 2024 | Aug 29, 2024 |
| 10-Q/A | Amended quarterly report | Aug 8, 2024 | Mar 31, 2024 |
| 10-Q | Quarterly report | Aug 8, 2024 | Jun 30, 2024 |
| 8-K |
Current report
Officer or director change
|
Jun 10, 2024 | Jun 4, 2024 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
May 28, 2024 | May 23, 2024 |
| 10-Q | Quarterly report | May 9, 2024 | Mar 31, 2024 |
| DEFA14A | Additional proxy material | May 2, 2024 | — |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
May 2, 2024 | Apr 30, 2024 |
| ARS | Annual report to shareholders | Apr 9, 2024 | Dec 31, 2023 |
| DEFA14A | Additional proxy material | Apr 9, 2024 | — |
| DEF 14A | Proxy statement | Apr 9, 2024 | May 23, 2024 |
| S-8 | Employee stock plan registration | Mar 21, 2024 | — |
| 10-K | Annual report | Mar 20, 2024 | Dec 31, 2023 |
| 8-K |
Current report
Other events
|
Jan 5, 2024 | Jan 5, 2024 |
| 10-Q | Quarterly report | Nov 7, 2023 | Sep 30, 2023 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Nov 2, 2023 | Nov 2, 2023 |
| S-8 | Employee stock plan registration | Aug 30, 2023 | — |
| 10-Q | Quarterly report | Aug 10, 2023 | Jun 30, 2023 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jun 9, 2023 | Jun 9, 2023 |
| 8-K |
Current report
Shareholder vote results
|
May 26, 2023 | May 26, 2023 |
| 10-Q | Quarterly report | May 11, 2023 | Mar 31, 2023 |
| ARS | Annual report to shareholders | Apr 14, 2023 | Dec 31, 2022 |
| DEFA14A | Additional proxy material | Apr 14, 2023 | — |
| DEF 14A | Proxy statement | Apr 14, 2023 | May 26, 2023 |
| 8-K |
Current report
Officer or director change
|
Apr 14, 2023 | Apr 12, 2023 |
| S-8 | Employee stock plan registration | Mar 23, 2023 | — |
| 10-K | Annual report | Mar 23, 2023 | Dec 31, 2022 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Feb 16, 2023 | Feb 16, 2023 |
| 8-K |
Current report
Material agreement
|
Dec 23, 2022 | Dec 23, 2022 |
| 424B5 | Prospectus supplement | Dec 23, 2022 | — |
| EFFECT | Filing | Dec 20, 2022 | — |
| CORRESP | Letter to the SEC | Dec 16, 2022 | — |
| UPLOAD | Letter from the SEC | Dec 15, 2022 | — |
| S-3 | Shelf registration | Dec 14, 2022 | — |
| 8-K |
Current report
Agreement ended
|
Dec 14, 2022 | Dec 9, 2022 |
| 424B5 | Prospectus supplement | Dec 8, 2022 | — |
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
Dec 7, 2022 | Dec 7, 2022 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Dec 7, 2022 | Dec 7, 2022 |
| 8-K |
Current report
Regulation FD disclosure
|
Nov 29, 2022 | Nov 29, 2022 |
| 10-Q | Quarterly report | Nov 10, 2022 | Sep 30, 2022 |
| 10-Q | Quarterly report | Aug 11, 2022 | Jun 30, 2022 |
| 8-K |
Current report
Shareholder vote results
|
Jun 17, 2022 | Jun 14, 2022 |
| 10-Q | Quarterly report | May 12, 2022 | Mar 31, 2022 |
| DEFA14A | Additional proxy material | Apr 28, 2022 | — |
| DEF 14A | Proxy statement | Apr 28, 2022 | Jun 14, 2022 |
| 8-K |
Current report
Officer or director change
|
Apr 14, 2022 | Apr 11, 2022 |
| EFFECT | Filing | Mar 18, 2022 | — |
| CORRESP | Letter to the SEC | Mar 16, 2022 | — |
| UPLOAD | Letter from the SEC | Mar 16, 2022 | — |
| S-3 | Shelf registration | Mar 14, 2022 | — |
| S-8 | Employee stock plan registration | Mar 14, 2022 | — |
| 10-K | Annual report | Mar 14, 2022 | Dec 31, 2021 |
| 10-Q | Quarterly report | Nov 10, 2021 | Sep 30, 2021 |
| 10-Q | Quarterly report | Aug 9, 2021 | Jun 30, 2021 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure, Other events
|
Jun 17, 2021 | Jun 15, 2021 |
| 10-Q | Quarterly report | May 6, 2021 | Mar 31, 2021 |
| 10-K | Annual report | Mar 25, 2021 | Dec 31, 2020 |
| S-8 | Employee stock plan registration | Feb 9, 2021 | — |
| 8-K |
Current report
Bylaw or fiscal year change, Other events
|
Feb 9, 2021 | Feb 9, 2021 |
| 424B4 | Prospectus | Feb 8, 2021 | — |
| S-1MEF | Filing | Feb 5, 2021 | — |
| EFFECT | Filing | Feb 4, 2021 | — |
| SEC STAFF LETTER | Filing | Feb 4, 2021 | — |
| CERT | 8a cert | Feb 3, 2021 | — |
| FWP | Free writing prospectus | Feb 3, 2021 | — |
| S-1/A | Amended registration statement | Feb 3, 2021 | — |
| CORRESP | Letter to the SEC | Feb 2, 2021 | — |
| CORRESP | Letter to the SEC | Feb 2, 2021 | — |
| 8-A12B | Filing | Feb 1, 2021 | — |
| CORRESP | Letter to the SEC | Feb 1, 2021 | — |
| S-1/A | Amended registration statement | Feb 1, 2021 | — |
| UPLOAD | Letter from the SEC | Jan 27, 2021 | — |
| CORRESP | Letter to the SEC | Jan 21, 2021 | — |
| CORRESP | Letter to the SEC | Jan 15, 2021 | — |
| S-1 | Registration statement | Jan 15, 2021 | — |
| SEC STAFF LETTER | Filing | Jan 5, 2021 | — |
| UPLOAD | Letter from the SEC | Jan 4, 2021 | — |
| DRSLTR | Filing | Dec 18, 2020 | — |
| DRS/A | Filing | Dec 18, 2020 | — |
| UPLOAD | Letter from the SEC | Dec 4, 2020 | — |
| DRS | Filing | Nov 6, 2020 | — |
| D | Filing | Jul 10, 2020 | — |
Showing 160 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- VOR (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- Boston, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1817229
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.